vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-935Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSОПЫТ ПРИМЕНЕНИЯ ИНГИБИТОРА КО-СТИМУЛЯЦИИ Т ЛИМФОЦИТОВ АБАТАЦЕПТА У БОЛЬНОЙ ПОЛИАРТИКУЛЯРНЫМ ВАРИАНТОМ ЮВЕНИЛЬНОГО РЕВМАТОИДНОГО АРТРИТАEXPERIENCE OF TREATMENT WITH INHIBITOR OF T-LYMPHOCYTES CO-STIMULATION ABATACEPT IN PATIENT WITH POLYARTICULAR TYPE OF JUVENILE RHEUMATOID ARTHRITISБзароваТ.М.BzarovaT.M.АлексееваЕ.И.AlexeevaE.I.ВалиеваС.И.ValievaS.I.ЧомахидзеА.М.ChomakhidzeA.M.ИсаеваК.Б.IsaevaK.B.ЛисицинА.О.LisitsynA.O.ДенисоваР.В.DenisovaR.V.Научный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowRussian Federation20101609201594Вопросы современной педиатрии147154Copyright © Бзарова Т., Алексеева Е., Валиева С., Чомахидзе А., Исаева К., Лисицин А., Денисова Р., 20102010Бзарова Т., Алексеева Е., Валиева С., Чомахидзе А., Исаева К., Лисицин А., Денисова Р.Bzarova T., Alexeeva E., Valieva S., Chomakhidze A., Isaeva K., Lisitsyn A., Denisova R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/935ReferencesBrewer E. J., Bass J., Baum J. Current proposed revision of JRA criteria. Arthritis Rheum. 1997; 20: 195.Brewer E. J., Bass J., Baum J. Current proposed revision of JRA criteria. Arthritis Rheum. 1997; 20: 195.Oliveira S., Ravelli A., Pistorio A. et al. Proxy reported healthrelated quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. Arthritis Rheum. 2007; 57: 35–43.Oliveira S., Ravelli A., Pistorio A. et al. Proxy reported healthrelated quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. Arthritis Rheum. 2007; 57: 35–43.Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369: 767–778.Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369: 767–778.Ruperto N., Levinson J. E., Ravelli A. et al. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. J. Rheumatol. 1997; 24: 945–951.Ruperto N., Levinson J. E., Ravelli A. et al. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. J. Rheumatol. 1997; 24: 945–951.Насонов Е.Л. Новые аспекты фармакотерапии ревматоидного артрита – блокада ко-стимуляции В-лимфоцитов. РМЖ. 2009; 17 (3): 2–7.Насонов Е.Л. Новые аспекты фармакотерапии ревматоидного артрита – блокада ко-стимуляции В-лимфоцитов. РМЖ. 2009; 17 (3): 2–7.Davies P., Zhou L., Abraham R. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J. Rheumatol. 2007; 34: 280–289.Davies P., Zhou L., Abraham R. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J. Rheumatol. 2007; 34: 280–289.Linsley P. S., Brady W., Urnes M. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991; 174 (3): 561–569.Linsley P. S., Brady W., Urnes M. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991; 174 (3): 561–569.Webb L. M., Walmsley M. J., Feldmann M. Prevention and amelioration of collagen–induced arthritis by blockade of the CD28 co–stimulatory pathway: requirement for both B7–1 and B7–2. Eur. J. Immunol. 1996; 26: 2320–2328.Webb L. M., Walmsley M. J., Feldmann M. Prevention and amelioration of collagen–induced arthritis by blockade of the CD28 co–stimulatory pathway: requirement for both B7–1 and B7–2. Eur. J. Immunol. 1996; 26: 2320–2328.Moreland L. W., Alten R., Bosch F. et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose finding, double blind, placebo controlled clinical trial evaluating CTLA–4Ig and LEA29Y eighty–five days after the first infusion. Arthritis Rheum. 2002; 46: 1470–1479.Moreland L. W., Alten R., Bosch F. et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose finding, double blind, placebo controlled clinical trial evaluating CTLA–4Ig and LEA29Y eighty–five days after the first infusion. Arthritis Rheum. 2002; 46: 1470–1479.Kremer J. M., Westhovens R., Leon M. et al. Treatment of rheumatoid arthritis by selective inhibition of T–cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 2003; 349: 1907–1915.Kremer J. M., Westhovens R., Leon M. et al. Treatment of rheumatoid arthritis by selective inhibition of T–cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 2003; 349: 1907–1915.Kremer J. M., Dougados M., Emery P. et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double blind, randomized, placebo controlled trial. Arthritis Rheum. 2005; 52: 2263–2271.Kremer J. M., Dougados M., Emery P. et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double blind, randomized, placebo controlled trial. Arthritis Rheum. 2005; 52: 2263–2271.Kremer J. M., Genant H. K., Moreland L. W. et al. Effects of abatacept in patients with methotrexate–resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 2006; 144: 865–876.Kremer J. M., Genant H. K., Moreland L. W. et al. Effects of abatacept in patients with methotrexate–resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 2006; 144: 865–876.Genovese M. C., Becker J. C., Schiff M. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 2005; 353: 1114–1123.Genovese M. C., Becker J. C., Schiff M. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 2005; 353: 1114–1123.Schiff M. H., Pritchard C., Huffstutter J. E. et al. The 6 month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-TNF therapy or were directly switched to abatacept: the ARRIVE trial. Ann. Rheum. Dis. 2009; 68 (11): 1708–1714.Schiff M. H., Pritchard C., Huffstutter J. E. et al. The 6 month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-TNF therapy or were directly switched to abatacept: the ARRIVE trial. Ann. Rheum. Dis. 2009; 68 (11): 1708–1714.Schiff M., Keiserman M., Codding C. et al. Efficacy and safety of abatacept or infliximab VS placebo in ATTEST: a phase III, multicentre, randomised, double blind, placebo controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 2008; 67: 1096–1103.Schiff M., Keiserman M., Codding C. et al. Efficacy and safety of abatacept or infliximab VS placebo in ATTEST: a phase III, multicentre, randomised, double blind, placebo controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 2008; 67: 1096–1103.Kremer J. M., Genant H. K., Moreland L. W. et al. Results of a two year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008; 58: 953–963.Kremer J. M., Genant H. K., Moreland L. W. et al. Results of a two year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008; 58: 953–963.Genant H. K., Peterfy C. G., Westhovens R. et al. Abatacept inhibits structural damage progression in rheumatoid arthritis: results from the long–term extension of the AIM trial. Ann. Rheum. Dis. 2008; 67: 1084–1089.Genant H. K., Peterfy C. G., Westhovens R. et al. Abatacept inhibits structural damage progression in rheumatoid arthritis: results from the long–term extension of the AIM trial. Ann. Rheum. Dis. 2008; 67: 1084–1089.Weinblatt M., Combe B., Covucci A. et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease modifying antirheumatic drugs: a one year randomized, placebo controlled study. Arthritis Rheum. 2006; 54: 2807–2816.Weinblatt M., Combe B., Covucci A. et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease modifying antirheumatic drugs: a one year randomized, placebo controlled study. Arthritis Rheum. 2006; 54: 2807–2816.Weinblatt M., Schiff M., Goldman A. et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis. 2007; 66: 228–234.Weinblatt M., Schiff M., Goldman A. et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis. 2007; 66: 228–234.Westhovens R. Robles M., Ximenes A. D. et al. Clinical efficacy and safety of abatacept in methotrexate naive patients with early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis. 2009; 68 (12): 1870–1877.Westhovens R. Robles M., Ximenes A. D. et al. Clinical efficacy and safety of abatacept in methotrexate naive patients with early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis. 2009; 68 (12): 1870–1877.Emery P., Durez P., Dougados M. et al. Efficacy of abatacept in delaying the development of rheumatoid arthritis (RA) in adult patients with undifferentiated inflammatory arthritis at high risk of developing RA [OP-0130]. Ann. Rheum. Dis. 2008; 67 (Suppl. II): 89.Emery P., Durez P., Dougados M. et al. Efficacy of abatacept in delaying the development of rheumatoid arthritis (RA) in adult patients with undifferentiated inflammatory arthritis at high risk of developing RA [OP-0130]. Ann. Rheum. Dis. 2008; 67 (Suppl. II): 89.Westhovens R., Kremer J., Moreland L. et al. Durable impact on disease activity and consistent safety through 5 years in abatacepttreated RA patients background methotrexate [FRI0171]. Ann. Rheum. Dis. 2008; 67 (Suppl. II): 341.Westhovens R., Kremer J., Moreland L. et al. Durable impact on disease activity and consistent safety through 5 years in abatacepttreated RA patients background methotrexate [FRI0171]. Ann. Rheum. Dis. 2008; 67 (Suppl. II): 341.Weisman M. H., Durez P., Hallegua D. et al. Reduction of inflammatory biomarker response by abatacept in the treatment of rheumatoid arthritis. J. Rheumatol. 2006; 33: 2162–2166.Weisman M. H., Durez P., Hallegua D. et al. Reduction of inflammatory biomarker response by abatacept in the treatment of rheumatoid arthritis. J. Rheumatol. 2006; 33: 2162–2166.Sibilia J., Westhovens R. Safety of T-cell co–stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin. Exp. Eheumatol. 2007; 25(Suppl. 46): 46–56.Sibilia J., Westhovens R. Safety of T-cell co–stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin. Exp. Eheumatol. 2007; 25(Suppl. 46): 46–56.Bristol–Myers Squibb: Summary of product characteristic. 2007. Доступно на: http://www.emea.europa.eu/humandocs/PDFs/EPAR/orencia?H–701–PI–en.pdf.Bristol–Myers Squibb: Summary of product characteristic. 2007. Доступно на: http://www.emea.europa.eu/humandocs/PDFs/EPAR/orencia?H–701–PI–en.pdf.Bigbee C. L., Gonchoroff D. G., Vratsanos G. et al. Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis Rheum. 2007; 56: 2557–2565.Bigbee C. L., Gonchoroff D. G., Vratsanos G. et al. Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis Rheum. 2007; 56: 2557–2565.Dixon WG, Hyrich KL, Watson KD, et al. Drug specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti–TNF therapy: results from the BSP biologics register (BSRBR). Ann. Rheum. Dis. 2008; 67 (Supp II): 178.Dixon WG, Hyrich KL, Watson KD, et al. Drug specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti–TNF therapy: results from the BSP biologics register (BSRBR). Ann. Rheum. Dis. 2008; 67 (Supp II): 178.Ruperto N., Lovell D. J., Quartier P. et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008; 372 (9636): 383–391.Ruperto N., Lovell D. J., Quartier P. et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008; 372 (9636): 383–391.
The authors declare that there are no conflicts of interest present.